X-linked lymphoproliferative disease (XLP), a genetic disorder characterized by immunodeficiency to Epstein-Barr virus (EBV) infection, has been linked to mutations in the SH2D1A gene. To search for the occurrence of SH2D1A mutations in Japan, we performed genetic analysis of the SH2D1A gene in 40 males presenting with severe EBV-associated illnesses, including fulminant infectious mononucleosis, EBV-positive lymphoma, and severe chronic active EBV infection. SH2D1A mutations were detected in 10 of these 40 patients. Five of these 10 cases were sporadic. Patients with SH2D1A mutations displayed severe acute infectious mononucleosis with hyperimmunoglobulin M, hypogammaglobulinemia, and B-cell malignant lymphoma. By contrast, chronic active EBV infection was not associated with SH2D1Amutations. XLP survivors exhibited normal levels of circulating EBV-DNA during convalescence, suggesting that SH2D1A protein is not directly responsible for control of EBV replication. Thus, genetic analysis of the SH2D1A gene is particularly useful in the diagnosis of sporadic cases and carriers of XLP.

X-linked lymphoproliferative disease (XLP, MIM 308240) is an inherited immunodeficiency characterized by extreme vulnerability to Epstein-Barr virus (EBV).1 About two-thirds of the patients develop fatal infectious mononucleosis (IM), and others manifest a diverse phenotype that includes malignant lymphoma, dysgammaglobulinemia, aplastic anemia, vasculitis, or lymphomatoid granulation.2 Recently, an SH2-domain–encoding gene, SH2D1A/SAP/DSHP, was identified as the causative gene of XLP.3-5 Most, if not all, patients with XLP have SH2D1A gene mutations.6 This information permits direct molecular diagnosis of XLP in patients and female carriers.

The clinical diagnosis for XLP is often difficult, especially in sporadic cases, because of the diverse presentation and the lack of unique findings in XLP. For example, fatal IM in XLP can be indistinguishable clinically and histologically from sporadic forms of virus-associated hemophagocytic syndrome.7 Sumegi et al6 reported that no SH2D1A mutations were detected in 25 males who manifested an XLP phenotype without a family history of XLP. Thus, it is not currently clear whether molecular diagnosis of XLP is applicable to patients with a sporadic XLP phenotype.

XLP patients have been reported from North America, Europe, the Middle East, and South America but, except for one recent case report,8 not from the highly populated countries of Asia.2 To search for the possible presence of XLP in Japan, we systematically screened 40 Japanese males with severe EBV-associated illnesses. The SH2D1A mutations were detected in 10 cases. Notably, 5 of these 10 cases had no family history of XLP.

Patients

Forty Japanese boys with severe EBV-associated illnesses were studied. All patients, except for 2 brothers, were unrelated. Five patients, including the 2 brothers, had a family history supporting an X-linked inheritance for the XLP phenotype. The study population included 3 groups: (group 1) 18 patients who had experienced severe acute IM (ages 0-17 years); (group 2) 5 patients with EBV genome–positive lymphoma (ages 0-8 years); and (group 3) 17 patients with severe chronic active EBV infection (CAEBV) (ages 1-12 years). The cases in group 1 met the diagnostic criteria for hemophagocytic lymphohistiocytosis9 or died immediately following an acute IM-like illness. All of these patients harbored the EBV genome in tissue specimens or displayed a serologic response suggestive of primary EBV infection: antibody positive for viral capsid antigen without detectable antibodies to EBV nuclear antigen. Lymphomas were defined as EBV-positive when the tissue harbored EBV genome detected by polymerase chain reaction or by in situ hybridization for EBV-encoded small RNAs.10 This group consisted of 3 B-cell lymphomas, including one Burkitt lymphoma, one Hodgkin disease, and one nasal lymphoma. CAEBV was diagnosed according to the previously described criteria.11-13 Briefly, these patients were characterized by prolonged or recurrent IM-like symptoms for more than one year, with hepatosplenomegaly, lymphoadenopathy, anemia, or cytopenia and with an unusual pattern of anti-EBV antibodies: high anti–viral capsid antigen and/or anti–early antigen, and low or absent anti-EBV nuclear antigen titers. None of these patients had an overt immunodeficient condition.

SH2DIA mutation analysis

Mutation analysis of the coding region in the SH2DIAgene was conducted on both complementary DNAs and genomic DNAs. Polymerase chain reaction conditions and primer sequences for amplifying the complementary DNA and the 4 exons of SH2DIAwere as previously reported.4 

In a survey of 40 boys with various forms of severe EBV-associated illnesses, we identified 10 patients from 9 kindreds that harboredSH2D1A gene mutations. The characteristics of these XLP patients are summarized in Table 1.

Table 1.

Features of patients with SH2D1A mutation

Clinical phenotypesCarrier detection
by genetic
diagnosis
SH2D1A mutationAge at
onset
(y)
DysgammaglobulinemiaClinical history
Case no.Family historyTypeNucleotide/(protein)IgG/IgA/IgM
Fulminant infectious mononucleosis
 
  1 + brother of case 2 Grandmother Nonsense Exon 2: 462C > T 1190/555/2010 Died after 19 days  
Mother (Arg 55Stop)  
  2 + brother of case 1 Grandmother Nonsense Exon 2: 462C > T 1661/756/1296 Died after 20 days  
Mother (Arg 55Stop)  
  3 − ND Nonsense Exon 2: 462C > T 1502/126/3604 Died after 18 days  
(Arg 55Stop) 
*− Mother Deletion Exons 1-4 1570/543/1200 Died after 21 days 
  5 − No carrier Deletion Exon 3: 584del(A) (frameshift) 1548/827/700 Died after 34 days 
  6 + 1 brother with EBV-negative lymphoma Mother Splice Exon 1: 416 C > T 938/635/926 Died after 21 days  
Intron 1: 5′ splice site  
(del 22bp, frameshift)  
  7 + 1 brother with Mother Missense Exon 1: 396G > T hypogammaglobulinemia In remission after 
   hypogammaglobulinemia and lymphoma Sister  (Asp 33Tyr)   since 4 years old  chemotherapy followed by PBSCT 
  8 − ND Missense Exon 1: 378G > A 1002/283/322 Died after about 1 month  
(Gly 27 Ser)  
  9 + 1 brother with hypogammaglobulinemia ND Missense Exon 1: 321C > G 1280/214/638 Stable at 17 years old under IVIG 
(His 8 Asp)  → hypogammaglobulinemia 
EBV-associated lymphoma
 
  10 − Mother Missense Exon 2: 445G > T 51/4/24 In remission after chemotherapy USCT planned  
(Gly 49 Val) 
Clinical phenotypesCarrier detection
by genetic
diagnosis
SH2D1A mutationAge at
onset
(y)
DysgammaglobulinemiaClinical history
Case no.Family historyTypeNucleotide/(protein)IgG/IgA/IgM
Fulminant infectious mononucleosis
 
  1 + brother of case 2 Grandmother Nonsense Exon 2: 462C > T 1190/555/2010 Died after 19 days  
Mother (Arg 55Stop)  
  2 + brother of case 1 Grandmother Nonsense Exon 2: 462C > T 1661/756/1296 Died after 20 days  
Mother (Arg 55Stop)  
  3 − ND Nonsense Exon 2: 462C > T 1502/126/3604 Died after 18 days  
(Arg 55Stop) 
*− Mother Deletion Exons 1-4 1570/543/1200 Died after 21 days 
  5 − No carrier Deletion Exon 3: 584del(A) (frameshift) 1548/827/700 Died after 34 days 
  6 + 1 brother with EBV-negative lymphoma Mother Splice Exon 1: 416 C > T 938/635/926 Died after 21 days  
Intron 1: 5′ splice site  
(del 22bp, frameshift)  
  7 + 1 brother with Mother Missense Exon 1: 396G > T hypogammaglobulinemia In remission after 
   hypogammaglobulinemia and lymphoma Sister  (Asp 33Tyr)   since 4 years old  chemotherapy followed by PBSCT 
  8 − ND Missense Exon 1: 378G > A 1002/283/322 Died after about 1 month  
(Gly 27 Ser)  
  9 + 1 brother with hypogammaglobulinemia ND Missense Exon 1: 321C > G 1280/214/638 Stable at 17 years old under IVIG 
(His 8 Asp)  → hypogammaglobulinemia 
EBV-associated lymphoma
 
  10 − Mother Missense Exon 2: 445G > T 51/4/24 In remission after chemotherapy USCT planned  
(Gly 49 Val) 

ND indicates not done; PBSCT, peripheral blood stem cell transplantation; IVIG, intravenous immunoglobulins; EBV, Epstein-Barr virus; USCT, umbilical stem cell transplantation.

*

This case was previously published.8 

Nonsense mutations (cases 1-3), large genomic deletion (case 4), smaller intragenic deletion (case 5), and splice site mutation (case 6) are expected to result in a truncated SH2D1A protein and, presumably, to a loss of proper SH2D1A function. All of the missense mutations (cases 7-10) are predicted to change the evolutionarily conserved SH2 domain and may alter the interactions between the SH2D1A protein with the cell surface molecules SLAM 4 and 2B4 14 on T and natural killer cells, respectively.

The nonsense mutation Arg55Stop has previously been reported as a hot spot for XLP mutations.6,15 The other 6 mutations noted here were novel and were not detected in unrelated control individuals screened from a total of 100 chromosomes. In case 4, sequencing of the complementary DNA revealed an aberrantly spliced product wherein the last 22 bases of exon 1 were deleted. In the genomic DNA, a synonymous substitution (416C>T) was identified, suggesting that a silent mutation created the new splice site due to a high Senapathy score around the mutated codon. A similar type of mutation was previously reported in another disease.16 

Five of the XLP patients (cases 3-5, 8, 10) had a negative family history suggestive for XLP. However, in those 3 sporadic cases (patients 4, 5, 10) where maternal blood was available for analysis, vertical transmission of the SH2D1A mutations was confirmed in cases 4 and 10. Until recently, XLP diagnosis rested on a family history of phenotypically affected male relatives in the maternal lineage, and XLP was considered to be extremely rare in Japan.2 The fact that half of the XLP patients in our series had no family history may explain this underestimation. Families with single affected XLP members may not be attributable to de novo mutations but to the scarcity of brothers resulting from the low birth rate in Japan. Indeed, the mutations found in the sporadic XLP cases were segregated within families. These results underscore the usefulness of a direct molecular diagnosis for XLP.

We examined the clinical features of the XLP. Nine of 10 mutations were detected in 18 patients with severe acute IM. One boy with EBV genome–positive Burkitt lymphoma also displayed a SH2D1Amutation. However, no SH2D1A mutations were detected in patients with CAEBV infection. The detection rate of SH2D1Amutation in patients with XLP phenotype varies (62%-97%) among previous reports.6 17 These proportions may be influenced by the existence of family history, family size, and each clinical symptom in the examined patients. The relatively low frequency of mutations in our series is likely due to the lack of family history for XLP in the majority of our study subjects.

Malignant lymphomas develop in approximately 30% of XLP patients, but it is unclear whether EBV plays any role in the lymphomagenesis. Burkitt lymphoma in case 10 showed EBERs positive and t(8;14)(q24;q32), whereas Burkitt lymphoma in the brother of case 6 was EBERs negative. In addition, the latter demonstrated EBV-negative serology and negative results of EBV PCR using blood and saliva. It was recently reported that lymphoproliferative diseases occurred in EBV-uninfected XLP patients.6 17 

Marked elevation of serum immunoglobulin M (IgM) and/or IgA levels or hypogammaglobulinemia was observed in all XLP cases. The onset of hypogammaglobulinemia was variable. In case 9, it developed following acute EBV infection. In case 6, it was found 4 years before fulminant IM developed. In case 10, it was noticed at the same time the EBV genome–positive lymphoma was diagnosed. These results suggest that hypogammaglobulinemia in XLP has a complex pathogenesis. By contrast, IgM elevations were noted in all cases with acute EBV infection, suggesting that hyper-IgM was related to the polyclonal activation of B cells induced by EBV. Thus, hypogammaglobulinemia and acute EBV infection with hyper-IgM were common clinical manifestations ofSH2D1A mutations.

XLP patients sometimes have chronic symptoms or recurrent EBV infection.18 To assess whether active EBV replication persists in XLP patients, we quantified circulating EBV load19 in the XLP survivors and compared the results with those from patients with acute severe EBV infection (Table2). The survivors carried normal levels of EBV-DNA copies during the convalescence phase. Recent studies have provided evidence suggesting that signal-transduction through 2B4, SH2D1A-associated receptor, was impaired in XLP patients and was indispensable for natural killer cell cytotoxicity.20,21Our results demonstrated that XLP patients could successfully suppress EBV replication after primary EBV infection, suggesting that the SH2D1A protein function is not required for proper control of EBV replication after primary infection.22 

Table 2.

Epstein-Barr virus loads in serum from patients with X-linked lymphoproliferative disease

Case no.Clinical phenotypeTime from
disease onset
Copy number of EBV
(copies/mL of serum)
Acute periods 
Fulminant IM 10 days 5.3 × 106 
Fulminant IM 18 days 3.2 × 105 
Fulminant IM 18 days 1.3 × 105 
Fulminant IM 34 days 3.0 × 104 
Convalescence periods  
Fulminant IM 14 years < 2.0 × 102 
10 EBV-associated Burkitt lymphoma (under chemotherapy) 4 months < 2.0 × 102 
7 months < 2.0 × 102 
Case no.Clinical phenotypeTime from
disease onset
Copy number of EBV
(copies/mL of serum)
Acute periods 
Fulminant IM 10 days 5.3 × 106 
Fulminant IM 18 days 3.2 × 105 
Fulminant IM 18 days 1.3 × 105 
Fulminant IM 34 days 3.0 × 104 
Convalescence periods  
Fulminant IM 14 years < 2.0 × 102 
10 EBV-associated Burkitt lymphoma (under chemotherapy) 4 months < 2.0 × 102 
7 months < 2.0 × 102 

IM indicates infectious mononucleosis. Other abbreviations are explained in Table 1.

We thank Dr Eiichi Ishii, Takeshi Shichijo, Sadao Suga, Kazumi Yamato, Kazuhide Ohta, Tadashi Matsubayashi, Masahiro Kikuchi, and Mika Makita for providing us with the specimens and clinical information on the patients and Reiko Hirochika for technical assistance. We are also indebted to Drs Tadao Arinami and Giovanna Tosato for critical discussion.

Supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan and grants from the Ministry of Health and Welfare of Japan, the Tsukuba University Project, and the Naito Foundation.

R.S. and H.K. contributed equally to this work.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Purtilo
DT
Cassel
CK
Yang
JP
Harper
R
X-linked recessive progressive combined variable immunodeficiency (Duncan's disease).
Lancet.
1
1975
935
940
2
Seemayer
TA
Gross
TG
Egeler
RM
et al
X-linked lymphoproliferative disease: twenty-five years after the discovery.
Pediatr Res.
38
1995
471
478
3
Coffey
AJ
Brooksbank
RA
Brandau
O
et al
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene.
Nat Genet.
20
1998
129
135
4
Sayos
J
Wu
C
Morra
M
et al
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.
Nature.
395
1998
462
469
5
Nichols
KE
Harkin
DP
Levitz
S
et al
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome.
Proc Natl Acad Sci U S A.
95
1998
13765
13770
6
Sumegi
J
Huang
D
Lanyi
A
et al
Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease.
Blood.
96
2000
3118
3125
7
Mroczek
EC
Weisenburger
DD
Grierson
HL
Markin
R
Purtilo
DT
Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome.
Arch Pathol Lab Med.
111
1987
530
535
8
Honda
K
Kanegane
H
Eguchi
M
et al
Large deletion of the X-linked lymphoproliferative disease gene detected by fluorescence in situ hybridization.
Am J Hematol.
64
2000
128
132
9
Henter
JI
Elinder
G
Ost
A
Diagnostic guidelines for hemophagocytic lymphohistiocytosis: the FHL Study Group of the Histiocyte Society.
Semin Oncol.
18
1991
29
33
10
Imai
S
Sugiura
M
Oikawa
O
et al
Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection.
Blood.
87
1996
1446
1457
11
Straus
SE
The chronic mononucleosis syndrome.
J Infect Dis.
157
1988
405
412
12
Okano
M
Matsumoto
S
Osato
T
Sakiyama
Y
Thiele
GM
Purtilo
DT
Severe chronic active Epstein-Barr virus infection syndrome.
Clin Microbiol Rev.
4
1991
129
135
13
Maia
DM
Peace-Brewer
AL
Chronic, active Epstein-Barr virus infection.
Curr Opin Hematol.
7
2000
59
63
14
Tangye
SG
Lazetic
S
Woollatt
E
Sutherland
GR
Lanier
LL
Phillips
JH
Human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP.
J Immunol.
162
1999
6981
6985
15
Yin
L
Ferrand
V
Lavoue
MF
et al
SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients.
Hum Genet.
105
1999
501
505
16
Li
X
Park
WJ
Pyeritz
RE
Jabs
EW
Effect on splicing of a silent FGFR2 mutation in Crouzon syndrome.
Nat Genet.
9
1995
232
233
17
Brandau
O
Schuster
V
Weiss
M
et al
Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP).
Hum Mol Genet.
8
1999
2407
2413
18
Purtilo
DT
Zelkowitz
L
Harada
S
et al
Delayed onset of infectious mononucleosis associated with acquired agammaglobulinemia and red cell aplasia.
Ann Intern Med.
101
1984
180
186
19
Kimura
H
Morita
M
Yabuta
Y
et al
Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.
J Clin Microbiol.
37
1999
132
136
20
Tangye
SG
Phillips
JH
Lanier
LL
Nichols
KE
Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome.
J Immunol.
165
2000
2932
2936
21
Parolini
S
Bottino
C
Falco
M
et al
X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.
J Exp Med.
192
2000
337
346
22
Sullivan
JL
The abnormal gene in X-linked lymphoproliferative syndrome.
Curr Opin Immunol.
11
1999
431
434

Author notes

Ryo Sumazaki, Dept of Pediatrics, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, 305-8575, Japan; e-mail: rsuma@md.tsukuba.ac.jp.

Sign in via your Institution